This biotech could help you retire early
By Mark Woodruff - January 17, 2014 | More on: MSB
You may not have come across the low-profile Mesoblast (ASX: MSB) yet, even though it is one of the
better-performing
stocks in the S&P ASX 200 Index (ASX: XJO). Its anonymity potentially represents an opportunity, as it often results in the mispricing of a stock.
Biotechnology stocks present difficulties in forming a valuation, because of uncertain future earnings and the inherently risky outcomes from ongoing clinical trials. So when risks are…
To keep reading, enter your email address or login below.
Enter your email below for FREE access to this article and all the content on the site. Also receive Take Stock, The Motley Fool's unique daily email on what's really happening with the share market. You may unsubscribe any time.
Click Here - It's Free!
Already a member? Login here.
By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about other products and services we think might interest you. Please read our Financial Services Guide (FSG) for more information.
This biotech could help you retire earlyBy Mark Woodruff -...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |